Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs Fox Corp Class B (FOX) Price & Performance

Ginkgo Bioworks Holdings IncTrade
Fox Corp Class BTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs Fox Corp Class B — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M), while Fox Corp Class B trades at $55.42 (market cap $25.05B). The key difference: Fox Corp Class B is far larger — about 48.6× Ginkgo Bioworks Holdings Inc's market cap, and Fox Corp Class B pays a 1.03% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

DNAFOX
Market Cap
$515.15M$25.05B
Sector
HealthMedia
52-Week High
$16.14$67.76
52-Week Low
$5.48$44.39
Enterprise Value
$617.10M$28.41B
Dividend Yield
1.03%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Fox Corp Class B

FOX stock trades at $57.03, up 3.0% in 24 hours, reflecting strong momentum. Recent earnings beats in Q4 2025, Q1 2026, and Q2 2026 underscore robust performance, with revenue reaching $16.30 billion in 2025. Technical indicators signal bullish trends, supported by moving averages, while RSI levels suggest potential overbought conditions. The company maintains solid profitability with a net income margin of 9.84% and ROE of 14.29%, though valuation metrics like P/E of 14.84 appear reasonable relative to peers.

Outlook remains positive driven by ad demand and digital growth, including Tubi and FOX One initiatives. Risks include reliance on advertising cycles and competitive pressures. Analyst consensus leans neutral with 42.86% buy ratings, but recent news highlights operational strength. Investors should weigh earnings consistency against market volatility and sector headwinds.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA

About Fox Corp Class B

Fox represents the assets not sold to Disney by the predecessor firm, Twenty First Century Fox. The remaining assets include Fox News, the FOX broadcast network, FS1 and FS2, Fox Business, Big Ten Network, 28 owned and operated local television stations of which 17 are affiliated with the Fox Network, and the Fox Studios lot. The Murdoch family continues to control the successor firm, which represents a large-scale bet on the value of live sports and news in the U.S. market.

Read more on FOX